Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 15, 2018-- SVd Once Weekly Demonstrates 17.8-month PFS and 83% ORR in the BOSTON Multiple Myeloma (MM) Population; 63% ORR in the Overall Study Population --
NEWTON, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three posters highlighting clinical data...
-
Jun 1, 2018Treatment with Selinexor Prolongs Progression-Free Survival Compared to Placebo (5.5 months versus 2.7 months, respectively) in Patients with Liposarcoma
NEWTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four posters will be presented at the...
-
Jun 1, 2018
NEWTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
May 31, 2018
NEWTON, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive...
-
May 24, 2018-- Antengene Rights Include All Human Oncology Indications for Selinexor, Eltanexor and KPT-9274, and Non-Oncology Human Indications for Verdinexor --
NEWTON, Mass. and SHANGHAI, China, May 24, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) (Karyopharm) and Antengene Corporation (Antengene), today announced their entry into...